Cantor Fitzgerald Reiterates “Neutral” Rating for Intra-Cellular Therapies (NASDAQ:ITCI)
Intra-Cellular Therapies (NASDAQ:ITCI – Get Free Report)‘s stock had its “neutral” rating reaffirmed by research analysts at Cantor Fitzgerald in a research note issued to investors on Wednesday,Benzinga reports. They currently have a $132.00 price objective on the biopharmaceutical company’s stock. Cantor Fitzgerald’s price objective points to a potential upside of 0.10% from the company’s […]
Intra-Cellular Therapies (NASDAQ:ITCI – Get Free Report)‘s stock had its “neutral” rating reaffirmed by research analysts at Cantor Fitzgerald in a research note issued to investors on Wednesday,Benzinga reports. They currently have a $132.00 price objective on the biopharmaceutical company’s stock. Cantor Fitzgerald’s price objective points to a potential upside of 0.10% from the company’s […]
